Clinical Trial Update: Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

View source ↗

Summary

This open-label pilot study assessed the pharmacokinetics of aripiprazole in adults with Bipolar I Disorder or schizophrenia; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Bipolar 1 Disorder, Schizophrenia | Status: COMPLETED